68 related articles for article (PubMed ID: 36171338)
1. Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma.
Chiesa S; Mangraviti A; Martini M; Cenci T; Mazzarella C; Gaudino S; Bracci S; Martino A; Della Pepa GM; Offi M; Gessi M; Russo R; Martucci M; Beghella Bartoli F; Larocca LM; Lauretti L; Olivi A; Pallini R; Balducci M; D'Alessandris QG
Sci Rep; 2022 Sep; 12(1):16265. PubMed ID: 36171338
[TBL] [Abstract][Full Text] [Related]
2. Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study.
Caccese M; Desideri I; Padovan M; Bruno F; Cerretti G; Fiorentino A; Denaro L; Chioffi F; Della Puppa A; Maccari M; Cavallin F; Coppola M; Pittaro A; Rudà R; Livi L; Lombardi G
J Neurooncol; 2023 Jun; 163(2):377-383. PubMed ID: 37264256
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib.
Lawson McLean A
J Neurooncol; 2023 Aug; 164(1):267-268. PubMed ID: 37561357
[No Abstract] [Full Text] [Related]
4. Clinical activity of regorafenib in elderly patients with recurrent glioblastoma.
Fasano M; Pirozzi M; Famiglietti V; Facchini S; Caterino M; Caroprese M; Barillaro A; Di Giovanni I; Auriemma A; Ileana Sara Fattoruso S; Somma T; Solari D; Bocchetti M; Conson M; Pacelli R; Ciardiello F; Addeo R
Mol Clin Oncol; 2023 Feb; 18(2):9. PubMed ID: 36761386
[TBL] [Abstract][Full Text] [Related]
5. Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?
Rudà R; Bruno F; Pellerino A; Pronello E; Palmiero R; Bertero L; Crasto S; Polo V; Vitaliani R; Trincia E; Internò V; Porta C; Soffietti R
J Neurooncol; 2022 Nov; 160(2):389-402. PubMed ID: 36309895
[TBL] [Abstract][Full Text] [Related]
6. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
Padovan M; Maccari M; Bosio A; De Toni C; Vizzaccaro S; Cestonaro I; Corrà M; Caccese M; Cerretti G; Zagonel V; Lombardi G
Eur J Cancer; 2023 Sep; 191():112959. PubMed ID: 37481865
[TBL] [Abstract][Full Text] [Related]
7. A case of glioblastoma harboring non-amplified epidermal growth factor receptor variant III: Critical molecular detection using RNA-based panel analysis.
Kirishima M; Akahane T; Takajo T; Higa N; Yonezawa H; Uchida H; Kamimura K; Hanaya R; Yoshimoto K; Higashi M; Yoshiura T; Tanimoto A
Pathol Res Pract; 2023 Aug; 248():154712. PubMed ID: 37499520
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.
Treiber H; von der Brelie C; Malinova V; Mielke D; Rohde V; Chapuy CI
Neurosurg Rev; 2022 Oct; 45(5):3201-3208. PubMed ID: 35725846
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma.
Martucci M; Ferranti AM; Schimperna F; Infante A; Magnani F; Olivi A; D'Alessandris QG; Gessi M; Chiesa S; Mazzarella C; Russo R; Giordano C; Gaudino S
Neuroradiology; 2023 Oct; 65(10):1439-1445. PubMed ID: 37247021
[TBL] [Abstract][Full Text] [Related]
10. Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling.
Morelli M; Lessi F; Franceschi S; Ferri G; Giacomarra M; Menicagli M; Gambacciani C; Pieri F; Pasqualetti F; Montemurro N; Aretini P; Santonocito OS; Di Stefano AL; Mazzanti CM
Cells; 2024 Mar; 13(6):. PubMed ID: 38534332
[TBL] [Abstract][Full Text] [Related]
11. Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors.
Friedman JS; Jun T; Rashidipour O; Huang KL; Ellis E; Kadaba P; Belani P; Nael K; Tsankova NM; Sebra R; Hormigo A
Cancer Immunol Immunother; 2023 Jun; 72(6):1893-1901. PubMed ID: 36707424
[TBL] [Abstract][Full Text] [Related]
12. Multi-Platform Classification of IDH-Wild-Type Glioblastoma Based on ERK/MAPK Pathway: Diagnostic, Prognostic and Therapeutic Implications.
Georgescu MM
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572759
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes.
Gaudino S; Marziali G; Giordano C; Gigli R; Varcasia G; Magnani F; Chiesa S; Balducci M; Costantini AM; Della Pepa GM; Olivi A; Russo R; Colosimo C
Front Radiol; 2021; 1():790456. PubMed ID: 37492166
[TBL] [Abstract][Full Text] [Related]
14. Deep-targeted gene sequencing reveals ARID1A mutation as an important driver of glioblastoma.
Xiao M; Cui X; Xu C; Xin L; Zhao J; Yang S; Hong B; Tan Y; Zhang J; Li X; Li J; Kang C; Fang C
CNS Neurosci Ther; 2024 Apr; 30(4):e14698. PubMed ID: 38600891
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract][Full Text] [Related]
16. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
Caccese M; Desideri I; Villani V; Simonelli M; Buglione M; Chiesa S; Franceschi E; Gaviani P; Stasi I; Caserta C; Brugnara S; Lolli I; Bennicelli E; Bini P; Cuccu AS; Scoccianti S; Padovan M; Gori S; Bonetti A; Giordano P; Pellerino A; Gregucci F; Riva N; Cinieri S; Internò V; Santoni M; Pernice G; Dealis C; Stievano L; Paiar F; Magni G; De Salvo GL; Zagonel V; Lombardi G
ESMO Open; 2024 Apr; 9(4):102943. PubMed ID: 38492275
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma Therapy: Past, Present and Future.
Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
